Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Gastric/Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06764875
What this trial is testing

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Who this might be right for
HER2-positive Gastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca 840
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07243938
What this trial is testing

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

Who this might be right for
Locally Advanced Rectal Cancer (LARC)Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaMetastatic Colorectal Cancer (mCRC)+1 more
Tao Zhang 70
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)Looking for participantsNCT06572319
What this trial is testing

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Zhejiang Cancer Hospital 35
Large-scale testing (Phase 3)Study completedNCT03675737
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC 1,579
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Testing effectiveness (Phase 2)Active Not RecruitingNCT05190445
What this trial is testing

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Who this might be right for
HER2-positive Gastric Cancer
Pieris Pharmaceuticals, Inc. 80
Testing effectiveness (Phase 2)Study completedNCT01503983
What this trial is testing

Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive

Who this might be right for
Stage IV Gastric Cancer With Metastasis
Fundación para el Progreso de la Oncología en Cantabria 45
Large-scale testing (Phase 3)Looking for participantsNCT06532006
What this trial is testing

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Who this might be right for
Gastroesophageal-junction CancerMonoclonal AntibodyGastric Cancer+1 more
Shanghai Henlius Biotech 550
Testing effectiveness (Phase 2)Ended earlyNCT04510285
What this trial is testing

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Who this might be right for
Esophagogastric TumorsGastric CancerGastric Tumor+7 more
Memorial Sloan Kettering Cancer Center 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT05034887
What this trial is testing

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06439550
What this trial is testing

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

Who this might be right for
HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University 42
Testing effectiveness (Phase 2)Looking for participantsNCT07551362
What this trial is testing

Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer

Who this might be right for
Advanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma
Beijing Biotech 36
Not applicableLooking for participantsNCT06846996
What this trial is testing

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo 260
Early research (Phase 1)Not Yet RecruitingNCT07036185
What this trial is testing

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Who this might be right for
Gastric/Gastroesophageal Junction CancerBreast CancerColorectal Cancer+3 more
Shanghai Bao Pharmaceuticals Co., Ltd. 66
Not applicableStudy completedNCT02731313
What this trial is testing

Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma

Who this might be right for
Gastric Cancer, Gastroesophageal Junction Cancer
Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Ended earlyNCT07040059
What this trial is testing

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
HER 2 Positive Gastric CancerGastroesophageal Junction Adenocarcinoma
Aurigene Discovery Technologies Limited 2
Testing effectiveness (Phase 2)Study completedNCT04276493
What this trial is testing

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Cancer
BeiGene 71
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Large-scale testing (Phase 3)Study completedNCT00680901
What this trial is testing

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Who this might be right for
Neoplasms, Gastrointestinal Tract
Novartis Pharmaceuticals 545
Next Page